NCT00566735View on ClinicalTrials.gov

The Use of Galantamine HBr (Reminyl) in Electroconvulsive Therapy: Impact on Mood and Cognitive Functioning

PHASE3CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

July 31, 2004

Primary Completion Date

January 31, 2008

Study Completion Date

January 31, 2008

Conditions
Major DepressionBipolar DepressionSchizoaffective Disorder
Interventions
DRUG

Razadyne

The starting dose of study medication is 4 mg twice a day

DRUG

Placebo

4 mg, 2 times a day

Trial Locations (1)

02114

Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

Ortho-McNeil Janssen Scientific Affairs, LLC

INDUSTRY

lead

Massachusetts General Hospital

OTHER

NCT00566735 - The Use of Galantamine HBr (Reminyl) in Electroconvulsive Therapy: Impact on Mood and Cognitive Functioning | Biotech Hunter | Biotech Hunter